Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vaxxinity, Inc. - Class A Common Stock
(NQ:
VAXX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vaxxinity, Inc. - Class A Common Stock
< Previous
1
2
Next >
Vaxxinity Issues Shareholder Letter
April 19, 2024
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
April 19, 2024
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
March 28, 2024
Presentation will address the Company’s clinical data in Parkinson’s disease
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
March 27, 2024
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
March 07, 2024
UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson’s patients
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
February 15, 2024
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
February 13, 2024
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
January 30, 2024
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida
January 18, 2024
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference
January 03, 2024
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity to Present at Upcoming November Medical and Investor Conferences
November 13, 2023
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 08, 2023
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity to Present at Upcoming Investor Conferences in September
August 29, 2023
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease
August 10, 2023
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 09, 2023
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director
July 27, 2023
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients
July 17, 2023
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease
June 22, 2023
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 09, 2023
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April
March 28, 2023
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates
March 27, 2023
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity Joins TransCelerate Research and Development Consortium
March 21, 2023
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia
March 20, 2023
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity to Present at Upcoming March Scientific and Medical Conferences
March 02, 2023
Vaxxinity to present new preclinical data on anti-tau Alzheimer’s vaccine candidate VXX-301 at AD/PD International Conference
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida
February 01, 2023
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity to Present at the 2023 J.P. Morgan Healthcare Conference
January 05, 2023
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612
December 02, 2022
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity to Host First Analyst and R&D Day in New York City on November 10, 2022
November 03, 2022
From
Vaxxinity, Inc.
Via
GlobeNewswire
Vaxxinity to Present at Upcoming Investor Conferences in November
November 01, 2022
From
Vaxxinity, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.